Myria delivers novel drug modalities combining the best of small molecules and biologics.
A large unmet medical need
Genetically Engineered Modular Molecule Scaffolds
Myria’s GEMMS
We recombine modular DNA elements derived from nonribosomal peptide synthetases (NRPS) and polyketide synthases (PKS) into functional new-to-nature molecules for pharmaceutical applications.
Highly parallel production, in vivo testing (millions), and structure-activity relationship (SAR) analysis enable iterative directed evolution cycles to optimize hits. This results in GEMMS (Genetically Engineered Modular Molecule Scaffolds).
Targets of interest
GEMMS are uniquely suited to address recalcitrant targets. We focus primarily on protein-protein interactions.
New chemical matter, built with biology.
Our advantages
Exclusive access to novel classes of therapeutic molecules
Proprietary knowledge and exclusive patent protection for GEMMS engineering
Unique platform technology to generate and test millions of novel molecules
Unparalleled ability to apply data-driven, targeted evolution to drug development
Drug modalities that can be produced biologically or with chemical synthesis according to needs